留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
中华医学会器官移植分会异种移植学组, 王维, 窦科峰, 等. 异种胰岛移植临床研究专家共识(2019专家建议版)[J]. 器官移植, 2019, 10(6): 672-677. doi: 10.3969/j.issn.1674-7445.2019.06.007
引用本文: 中华医学会器官移植分会异种移植学组, 王维, 窦科峰, 等. 异种胰岛移植临床研究专家共识(2019专家建议版)[J]. 器官移植, 2019, 10(6): 672-677. doi: 10.3969/j.issn.1674-7445.2019.06.007
Xenotransplantation Group in Branch of Organ Transplantation of Chinese Medical Association, Wang Wei, Dou Kefeng, et al. Experts consensus on islet xenotransplantation clinical trial (2019 expert advice edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(6): 672-677. doi: 10.3969/j.issn.1674-7445.2019.06.007
Citation: Xenotransplantation Group in Branch of Organ Transplantation of Chinese Medical Association, Wang Wei, Dou Kefeng, et al. Experts consensus on islet xenotransplantation clinical trial (2019 expert advice edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(6): 672-677. doi: 10.3969/j.issn.1674-7445.2019.06.007

异种胰岛移植临床研究专家共识(2019专家建议版)

doi: 10.3969/j.issn.1674-7445.2019.06.007
基金项目: 

湖南省重大专项 2018SK1020

详细信息
    通讯作者:

    王维,男,1960年生,主任医师,教授,博士研究生导师,研究方向为异种胰岛移植、细胞治疗,Email:cjr.wangwei@vip.163.com

  • 中图分类号: R617, R136.4, R587.1

Experts consensus on islet xenotransplantation clinical trial (2019 expert advice edition)

  • 摘要: 为了顺利推进异种胰岛移植的临床研究,根据相关法律和规范,中华医学会器官移植学分会异种移植学组从总则、异种胰岛移植临床研究项目的申请与审批,对供体的要求、伦理要求,临床研究的技术和相关设备标准、生物安全性标准、项目的实施、项目管理等方面,制定了异种胰岛移植临床研究专家共识(2019专家建议版)。

     

  • [1] COOPER DK, CASU A. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--chapter 4: pre-clinical efficacy and complication data required to justify a clinical trial[J]. Xenotransplantation, 2009, 16(4):229-238. DOI: 10.1111/j.1399-3089.2009.00543.x.
    [2] MATSUMOTO S, TAN P, BAKER J, et al. Clinical porcine islet xenotransplantation under comprehensive regulation[J]. Transplant Proc, 2014, 46(6):1992-1995. DOI: 10.1016/j.transproceed.2014.06.008.
    [3] COOPER DK, MATSUMOTO S, ABALOVICH A, et al. Progress in clinical encapsulated islet xenotransplantation[J]. Transplantation, 2016, 100(11):2301-2308. doi: 10.1097/TP.0000000000001371
    [4] U.S. Department of Health and Human Services Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: source animal, product, preclinical, and clinical issues concerning the use of xenotransplantation products in humans[EB/OL]. (2016-12-01). https://www.fda.gov/media/102126/download.
    [5] LARIJANI B, ARJMAND B, AMOLI MM, et al. Establishing a cGMP pancreatic islet processing facility: the first experience in Iran[J]. Cell Tissue Bank, 2012, 13(4):569-575. DOI: 10.1007/s10561-011-9273-1.
    [6] Department of Health and Human Services Food and Drug Administration. PHS guideline on infectious disease issues in xenotransplantation[EB/OL]. (2019-06-30). https://www.fda.gov/media/73803/download.
    [7] FISHMAN JA, SCOBIE L, TAKEUCHI Y. Xenotransplantation-associated infectious risk: a WHO consultation[J]. Xenotransplantation, 2012, 19(2):72-81. DOI: 10.1111/j.1399-3089.2012.00693.x.
    [8] FISHMAN JA. Infectious disease risks in xenotransplantation[J]. Am J Transplant, 2018, 18(8): 1857-1864. DOI: 10.1111/ajt.14725.
    [9] YANG L, GÜELL M, NIU D, et al. Genome-wide inactivation of porcine endogenous retroviruses (PERVs)[J]. Science, 2015, 350(6264):1101-1104. DOI: 10.1126/science.aad1191.
    [10] Second WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials[EB/OL]. (2011-10-17).http://158.232.12.119/transplantation/xeno/report2nd_global_consultation_xtx.pdf.
    [11] World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects[J]. JAMA, 2013, 310(20):2191-2194. DOI: 10.1001/jama.2013.281053.
    [12] First WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials: Changsha, China, 19-21 November 2008. The Changsha Communiqué[J]. Xenotransplantation, 2009, 16(2):61-63. DOI: 10.1111/j.1399-3089.2009.00520.x.
    [13] HERING BJ, O' CONNELL PJ. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 6: patient selection for pilot clinical trials of islet xenotransplantation[J]. Xenotransplantation, 2016, 23(1):60-76. DOI: 10.1111/xen.12228.
    [14] TUCH BE, KEOGH GW, WILLIAMS LJ, et al. Safety and viability of microencapsulated human islets transplanted into diabetic humans[J]. Diabetes Care, 2009, 32(10):1887-1889. DOI: 10.2337/dc09-0744.
    [15] GARKAVENKO O, CROXSON MC, IRGANG M, et al. Monitoring for presence of potentially xenotic viruses in recipients of pig islet xenotransplantation[J]. J Clin Microbiol, 2004, 42(11):5353-5356. doi: 10.1128/JCM.42.11.5353-5356.2004
    [16] PIERSON RN 3RD, DORLING A, AYARES D, et al. Current status of xenotransplantation and prospects for clinical application[J]. Xenotransplantation, 2009, 16(5):263-280. DOI: 10.1111/j.1399-3089.2009.00534.x.
    [17] SPIZZO T, DENNER J, GAZDA L, et al. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-- Chapter 2a: source pigs--preventing xenozoonoses[J]. Xenotransplantation, 2016, 23(1):25-31. DOI: 10.1111/xen.12223.
    [18] BOTTINO R, KNOLL MF, GRAEME-WILSON J, et al. Safe use of anti-CD154 monoclonal antibody in pig islet xenotransplantation in monkeys[J]. Xenotransplantation, 2017, 24(1). DOI: 10.1111/xen.12283.
    [19] SAMY KP, BUTLER JR, LI P, et al. The role of costimulation blockade in solid organ and islet xenotransplantation[J]. J Immunol Res, 2017:8415205. DOI: 10.1155/2017/8415205.
    [20] SCHWARZ C, MAHR B, MUCKENHUBER M, et al. Belatacept/CTLA4Ig: an update and critical appraisal of preclinical and clinical results[J]. Expert Rev Clin Immunol, 2018, 14(7):583-592. DOI: 10.1080/17446 66X.2018.1485489.
    [21] THOMSON AW, EZZELARAB MB. A tale of two pathways: renewing the promise of anti-CD40L blockade[J]. Am J Transplant, 2017, 17(5):1156-1157. DOI: 10.1111/ajt.14217.
    [22] WYNYARD S, NATHU D, GARKAVENKO O, et al. Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand[J]. Xenotransplantation, 2014, 21(4):309-323. DOI: 10.1111/xen.12102.
    [23] KOURTZELIS I, MAGNUSSON PU, KOTLABOVA K, et al. Regulation of instant blood mediated inflammatory reaction (IBMIR) in pancreatic islet xeno-transplantation: points for therapeutic interventions[M]// LAMBRIS J, EKDAHL K, RICKLIN D, et al. Immune responses to biosurfaces. advances in experimental medicine and biology. Berlin: Springer, Cham, 2015: 865.
    [24] HAWTHORNE WJ, COWAN PJ, BÜHLER LH, et al. Third WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials, Changsha, Hunan, China December 12-14, 2018: "The 2018 Changsha Communiqué" The 10-Year Anniversary of The International Consultation on Xenotransplantation[J]. Xenotransplantation, 2019, 26(2):e12513. DOI:10. 1111/xen.12513.
    [25] SHIN TH, BAEK EJ, CORAT MAF, et al. CRISPR/Cas9 PIG -A gene editing in nonhuman primate model demonstrates no intrinsic clonal expansion of PNH HSPCs[J]. Blood, 2019, 133(23):2542-2545. DOI: 10.1182/blood.2019000800.
  • 加载中
计量
  • 文章访问数:  285
  • HTML全文浏览量:  95
  • PDF下载量:  77
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-08-20
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2019-11-15

目录

    /

    返回文章
    返回